Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used drugs Ozempic and Wegovy, following ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Veru Inc. VERU recently announced the selection of a novel modified-release oral formulation for enobosarm for chronic weight loss management. Enobosarm is a selective androgen receptor modulator ...

Many Mounjaro users are looking into alternative medications following news of a 170 percent price increase in the UK ...

Yesterday, US pharmaceutical giant Lilly announced the cost would soar from September 1, with a month's supply of the highest ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

MAKERS of the fat jab Wegovy say they will not increase the price of the drug when the cost of rival Mounjaro doubles next ...

How will the Mounjaro price increase affect your cost? What have companies like Juniper, MedExpress and Asda Online Doctor ...

In a virtual meeting with health care providers and community partners Thursday afternoon, North Carolina Health Secretary ...